TSVT 2seventy bio, Inc.

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. 2seventy bio, Inc.(NasdaqGS:TSVT.V) operates independently of bluebird bio, Inc. as of November 4, 2021.

$15.88  +0.31 (1.99%)
As of 11/25/2022 13:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—General
Index country:  USA
Country of incorporation:  
IPO date:  11/05/2021
Outstanding shares:  37,916,693
Average volume:  400,417
Market cap:   $590,362,910
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BMTXV88
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy